Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Plasma Cell Myeloma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Bortezomib, Alvocidib Hydrochloride, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 5
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania • Charleston, South Carolina + 1 more

Conditions: Obesity, Endothelial Dysfunction, Decreased Vascular Flow
Interventions: Adenosine, Regadenoson; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 88 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Peripheral Vascular Diseases
Interventions: G-CSF, Placebo, Aspirin, Clopidogrel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: DFRF4539A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 5 more

Conditions: End Stage Renal Disease
Interventions: Expedial Vascular Access Graft; Device
Lead sponsor: LeMaitre Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Miami, Florida • Baton Rouge, Louisiana • The Bronx, New York + 4 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 40 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma, Osteosarcoma, Ewing Sarcoma of Bone
Interventions: Gemcitabine, 9-ING-41, Docetaxel; Drug
Lead sponsor: Brown University; Other
Eligibility: 10 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions: Exercise; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: VELCADE, Lenalidomide, Dexamethasone, DVT prophylaxis, Bisphosphonates, Liposomal doxorubicin; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Memphis, Tennessee • Nashville, Tennessee

Conditions: Coronary Artery Disease (CAD)
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more

Conditions: Chest Pain, Angina Pectoris, Myocardial Infarction
Interventions: coronary artery computed tomography angiogram, single photon emission computed tomography; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 25 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Multiple Myeloma
Interventions: LY2127399; Biological
Lead sponsor: Applied Molecular Evolution; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Iowa City, Iowa + 3 more

Conditions: Multiple Myeloma
Interventions: PDR001, CJM112, LCL161; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona • Nashville, Tennessee

Conditions: Leukemia, Acute Leukemia, Acute Lymphocytic Leukemia, Multiple Myeloma, Hematological Cancers, Psychological Distress
Interventions: Writing A (Experimental informative writing), Writing B (Experimental noninformative writing), Writing C (Control informative writing), Writing D (Control noninformative writing); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Hackensack, New Jersey • New York, New York • Chapel Hill, North Carolina

Conditions: Pulmonary Embolism
Interventions: Rivaroxaban, Warfarin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 98,947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aphasia, Acquired
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Infusion of Activated & Expanded Autologous T Cells; Procedure
Lead sponsor: Xcyte Therapies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 3 more

Conditions: Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
Interventions: Dexrazoxane, Doxorubicin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stroke
Interventions: Reactive Perturbations, Proactive Perturbations; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Myeloma
Interventions: Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: Nivolumab 240mg, Radiation therapy; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronavirus Disease 2019
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Search by objective public record fields.

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

Coronary Artery Disease (CAD) in Women Marathon Runners

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Study of Coronary Artery Computed Tomography to Diagnose Emergency Chest Pain

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

Effects of rTMS on Brain Activation in Aphasia

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Post-stroke Perturbation Training

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood